The delivery of hydrogen sulfide (H2S) to liver is expected for the treatment of hepatic diseases. K. Sakai et al. developed two types of sulfo-albumins, macromolecular H2S prodrugs, for hepatic and intrahepatic targeting of H2S. Sulfide groups (source of H2S) were covalently bound to succinylated (Suc) and galactosylated (Gal) bovine serum albumin (BSA) for targeted delivery of H2S to hepatic nonparenchymal cells and parenchymal cells, respectively. Their results demonstrated targeted delivery of H2S prodrug to a specific type of liver cells using the chemical modification of targeting ligands.